| Nov 13 |
Enliven Therapeutics GAAP EPS of -$0.48 beats by $0.02
|
| Nov 13 |
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
|
| Nov 7 |
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
|
| Oct 18 |
Why this largely unknown company is one analyst's top biotech pick
|
| Sep 30 |
Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial
|
| Sep 28 |
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
|
| Sep 26 |
Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going
|
| Sep 18 |
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
|
| Sep 9 |
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
|
| Sep 4 |
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?
|
